[1]邵毅,石文卿,肖昂.解读“亚洲人群糖尿病黄斑水肿管理专家小组共识”[J].眼科新进展,2021,41(9):801-805.[doi:10.13389/j.cnki.rao.2021.0168]
 SHAO Yi,SHI Wenqing,XIAO Ang.Diabetic macular edema management in Asian populations: Expert panel consensus guidelines[J].Recent Advances in Ophthalmology,2021,41(9):801-805.[doi:10.13389/j.cnki.rao.2021.0168]
点击复制

解读“亚洲人群糖尿病黄斑水肿管理专家小组共识”/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年9期
页码:
801-805
栏目:
述评
出版日期:
2021-09-05

文章信息/Info

Title:
Diabetic macular edema management in Asian populations: Expert panel consensus guidelines
作者:
邵毅石文卿肖昂
330006 江西省南昌市,南昌大学第一附属医院眼科
Author(s):
SHAO YiSHI WenqingXIAO Ang
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
关键词:
黄斑水肿亚洲人群共识
Keywords:
macular edema Asian population consensus
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2021.0168
文献标志码:
A
摘要:
随着糖尿病患病率的增加,全球糖尿病视网膜病变和糖尿病黄斑水肿患者人数日益增长,而亚洲糖尿病人口的增长预计将比全球平均增长更严重,主要归因于糖尿病发病较早、患者缺乏筛查意识导致就诊延迟、费用昂贵导致患者依从性差以及由于缺乏健康教育而对糖尿病的了解不足等因素。如何基于以上原因以及治疗方面进行规范管理一直是众多眼科医师的困扰。本文将对最新的“亚洲人群糖尿病黄斑水肿管理专家小组共识”进行解读,旨在帮助眼科医师对亚洲人群糖尿病黄斑水肿患者进行规范化诊治。
Abstract:
As the increased prevalence of diabetes, the number of patients with diabetic retinopathy and diabetic macular edema is growing globally. Notably, the growth of the diabetes patients in Asian population is expected to be severer than the global average growth, which is mainly attributed to early onset of diabetes, delayed medical visit due to the lacked screening awareness, poor compliance due to high medical cost, and poor understanding of diabetes due to the lacked health education. Therefore, it has been a challenge for many ophthalmologists to standardize the management of diabetes and the ophthalmic complications. This study aims to interpret the expert panel consensus guidelines on the diabetic macular edema management in Asian populations, thus helping ophthalmologists to standardize the management of Asian patients with diabetic macular edema.

参考文献/References:

[1] 肖康,梁申芝,万光明,王莉.玻璃体内注射阿柏西普治疗顽固性糖尿病黄斑水肿的疗效[J].眼科新进展,2020,40(8):744-746.
XIAO K,LIANG S Z,WAN G M,WANG L.Efficiency of intravitreal aflibercept for the treatment of refractory diabetic macular edema[J].Rec Adv Ophthalmol,2020,40(8):744-746.
[2] SCHMIDT-ERFURTH U,GARCIA-ARUMI J,BANDELLO F,BERG K,CHAKRAVARTHY U,GERENDAS B S,et al.Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) [J].Ophthalmologica,2017,237(4):185-222.
[3] ELNAHRY A G,ELNAHRY G A.Optical coherence tomography angiography of macular perfusion changes after anti-VEGF therapy for diabetic macular edema:a systematic review [J].J Diabetes Res,2021,2021:6634637.
[4] URBANCIC M,KLOBUCAR P,ZUPAN M,URBANCIC K,LAVRIC A.Anti-VEGF treatment of diabetic macular edema:two-year visual outcomes in routine clinical practice[J].J Ophthalmol,2020,2020:6979758.
[5] WHITCUP S M,CIDLOWSKI J A,CSAKY K G,AMBATI J.Pharmacology of corticosteroids for diabetic macular edema [J].Invest Ophthalmol Vis Sci,2018,59(1):1-12.
[6] CHEUNG G C,YOON Y H,CHEN L J,CHEN S J,GEORGE T M,LAI T Y,et al.Diabetic macular oedema:evidence-based treatment recommendations for Asian countries [J].Clin Exp Ophthalmol,2018,46(1):75-86.
[7] CHHABLANI J,WONG K,TAN G S,SUDHALKAR A,LAUDE A,CHEUNG C M G,et al.Diabetic macular edema management in Asian population:expert panel consensus guidelines[J].Asia Pac J Ophthalmol (Phila),2020,9(5):426-434.
[8] 宋潇宇,朴天华.难治性糖尿病黄斑水肿治疗策略的研究进展[J].牡丹江医学院学报,2021,42(3):125-127,157.
SONG X Y,PU T H.Research progress of treatment strategies for refractory diabetic macular edema[J].J MuDanJiang Med Univ,2021,42(3):125-127,157.
[9] TING D S,CHEUNG G C,WONG T Y.Diabetic retinopathy:global prevalence,major risk factors,screening practices and public health challenges:a review [J].Clin Exp Ophthalmol,2016,44(4):260-277.
[10] URBANCIC M,GARDASEVIC TOPCIC I.Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective [J].Clin Ophthalmol,2019,13:829-840.
[11] KODJIKIAN L,BELLOCQ D,BANDELLO F,LOEWENSTEIN A,CHAKRAVARTHY U,KOH A,et al.First-line treatment algorithm and guidelines in center-involving diabetic macular edema [J].Eur J Ophthalmol,2019,29(6):573-584.
[12] ROMERO-AROCA P,BAGET-BERNALDIZ M,PAREJA-RIOS A,LOPEZ-GALVEZ M,NAVARRO-GIL R,VERGES R.Diabetic macular edema pathophysiology:vasogenic versus inflammatory [J].J Diabetes Res,2016,2016:2156273.
[13] DARUICH A,MATET A,MOULIN A,KOWALCZUK L,NICOLAS M,SELLAM A,et al.Mechanisms of macular edema:beyond the surface [J].Prog Retin Eye Res,2018,63:20-68.
[14] BUX A V,FORTUNATO F,BARONE A,RUSSO V,DELLE NOCI N,IACULLI C.Early treatment with dexamethasone intravitreal implants in diabetic macular edema:naive versus refractory patients [J].Eur J Ophthalmol,2021,2021:11206721211024804.
[15] MEDINA-BAENA M,CEJUDO-CORBALAN O,GARCIA-PULIDO J I,HUERTOS-CARRILLO M J,GIRELA-LOPEZ E.Intravitreal dexamethasone implant in naive and previously treated patients with diabetic macular edema:a retrospective study [J].Int J Ophthalmol,2020,13(10):1597-1605.
[16] FURINO C,BOSCIA F,REIBALDI M,ALESSIO G.Intravitreal therapy for diabetic macular edema:an update [J].J Ophthalmol,2021,2021:6654168.
[17] MISHRA S K,SINHA S,CHAUHAN R,KUMAR A.Intravitreal dexamethasone implant versus intravitreal ranibizumab injection for treatment of non-proliferative diabetic macular edema:a prospective,randomized and blinded trial [J].Curr Drug Deliv,2020,[Online ahead of print].
[18] VUJOSEVIC S,SIMO R.Local and systemic inflammatory biomarkers of diabetic retinopathy:an integrative approach[J].Invest Ophthalmol Vis Sci,2017,58(6):BIO68-BIO75.
[19] TAKAYA K,SUZUKI Y,MIZUTANI H,SAKURABA T,NAKAZAWA M.Long-term results of vitrectomy for removal of submacular hard exudates in patients with diabetic maculopathy [J].Retina,2004,24(1):23-29.
[20] YU Q,WANG F,ZHOU L,YANG J,LIU K,XU X.Quantification of diabetic retinopathy lesions in DME patients with intravitreal conbercept treatment using deep learning[J].Ophthalmic Surg Lasers Imaging Retina,2020,51(2):95-100.
[21] YOON C K,SAGONG M,SHIN J P,LEE S J,LEE J E,LEE J E,et al.Title:efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema [J].BMC Ophthalmol,2021,21(1):41.
[22] BRESSLER S B,GLASSMAN A R,ALMUKHTAR T,BRESSLER N M,FERRIS F L,GOOGE J M Jr,et al.Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema [J].Am J Ophthalmol,2016,164:57-68.
[23] LAUGESEN C S,OSTRI C,BRYNSKOV T,LUND-ANDERSEN H,LARSEN M,VORUM H,et al.Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes [J].Acta Ophthalmol,2017,95(1):28-32.
[24] REZKALLAH A,MALCLES A,DOT C,VOIRIN N,AGARD E,VIE A L,et al.Evaluation of efficacy and safety of dexamethasone intravitreal implants of vitrectomized and nonvitrectomized eyes in a real-world study [J].J Ocul Pharmacol Ther,2018,34(8):596-602.
[25] SUDHALKAR A,KODJIKIAN L,CHHABLANI J,BHOJWANI D,VASAVADA A.Intraocular dexamethasone implant position in situ and ocular hypertension [J].Retina,2018,38(12):2343-2349.
[26] BILGIC A,SUDHALKAR A,KODJIKIAN L,VASAVADA V,VASAVADA S,BHOJWANI D,et al.Pro Re Nata Dexamethasone implant for treatment-Naive Phakic Eyes with diabetic macular edema:a prospective study[J].Ophthalmol Retina,2019,3(11):929-937.
[27] PACELLA F,PACELLA E,TROVATO BATTAGLIOLA E,MALVASI M,SCALINCI S Z,TURCHETTI P,et al.Efficacy and safety of intravitreal Fluocinolone Acetonide microimplant (ILUVIEN?) in patients with chronic diabetic macular edema:1 year follow-up [J].Eur J Ophthalmol,2021,2021:11206721211020203.
[28] MALCLES A,DOT C,VOIRIN N,VIE A L,AGARD E,BELLOCQ D,et al.Safety of intravitreal dexamethasone implant (OZURDEX):the SAFODEX study.Incidence and risk factors of ocular hypertension[J].Retina,2017,37(7):1352-1359.
[29] MACCUMBER M W.Intraocular pressure and anti-vascular endothelial growth factor injections [J].Ophthalmol Retina,2020,4(9):859-860.
[30] OZDEMIR O,ARMAN A,TAYMAN C.Intraocular pressure effect of anti-vascular endothelial growth factor injection for aggressive posterior retinopathy of prematurity [J].Graefes Arch Clin Exp Ophthalmol,2021,[Online ahead of print].
[31] BRESSLER S B,ALMUKHTAR T,BHORADE A,BRESSLER N M,GLASSMAN A R,HUANG S S,et al.Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment [J].JAMA Ophthalmol,2015,133(5):589-597.
[32] 陈敏华,张小花,谢青,彭立.地塞米松玻璃体内植入剂对比雷珠单抗治疗糖尿病黄斑水肿的疗效及安全性的荟萃分析[J].临床与病理杂志,2021,41(3):615-622.
CHEN M H,ZHANG X H,XIE Q,PENG L.Efficacy and safety of intravitreal dexamethasone implant versus ranibizumab in diabetic macular edema:a Meta-analysis[J].J Clin Pathol Res,2021,41(3):615-622.
[33] AARONSON A,TAIPALE C,ACHIRON A,AALTONEN V,GRZYBOWSKI A,TUUMINEN R.Relationship between prolonged intraocular inflammation and macular edema after cataract surgery [J].Transl Vis Sci Technol,2021,10(7):15.
[34] ZIEMSSEN F,AGOSTINI H,Boyer R.Three-year,randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J].Ophthalmology,2015,122(3):e20-21.
[35] KODJIKIAN L,BELLOCQ D,MATHIS T.Pharmacological management of diabetic macular edema in real-life observational studies[J].Biomed Res Int,2018,2018:8289253.
[36] FURINO C,BOSCIA F,NIRO A,D’ADDARIO M,GRASSI M O,SAGLIMBENE V,et al.Diabetic macular edema and cataract surgery:phacoemulsification combined with dexamethasone intravitreal implant compared with standard phacoemulsification [J].Retina,2021,41(5):1102-1109.
[37] FALLICO M,AVITABILE T,CASTELLINO N,LONGO A,RUSSO A,BONFIGLIO V,et al.Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema:the dexcat study [J].Acta Ophthalmol,2021,99(1):e74-e80.

相似文献/References:

[1]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[2]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[3]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[4]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[5]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[6]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[7]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[8]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[9]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[10]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
 CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(9):772.[doi:10.13389/j.cnki.rao.2014.0213]

备注/Memo

备注/Memo:
国家自然科学基金资助(编号:81660158);中央引导地方科技发展资金(编号:20211ZDG02003);江西省杰出青年人才计划(编号:20192BCBL23020);江西省重点研发项目(编号: 20181BBG70004,20203BBG73059)
更新日期/Last Update: 2021-09-05